Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
18 hedge funds and large institutions have $997K invested in Sonnet BioTherapeutics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
18% less funds holding
Funds holding: 22 → 18 (-4)
56% less capital invested
Capital invested by funds: $2.26M → $997K (-$1.27M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.5K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$22.9K |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$501K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$114K |
| 3 |
Millennium Management
New York
|
-$102K |
| 4 |
VF
Virtu Financial
New York
|
-$42K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$30.8K |
SONN Hedge Fund Activity: Q2 2022 in Review
18 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2022, worth a combined $997K — down 56% from $2.26M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SONN and 0 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $59.5K. The largest seller was Renaissance Technologies, cutting an estimated $501K.
- 18 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2022, down from 22 in Q1 2022.
- Funds reported $997K of Sonnet BioTherapeutics stock for Q2 2022, down 56% quarter-over-quarter.
- 0 funds opened new Sonnet BioTherapeutics positions in Q2 2022 and 4 closed out, a net change of -4 holders.
- The largest Sonnet BioTherapeutics buyer in Q2 2022 was Vanguard Group, an estimated $59.5K added.
- The largest Sonnet BioTherapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $501K sold.
Based on aggregated 13F filings for Q2 2022.